Article
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2021
Koga Takamasa, Suda Kenichi, Fujino Toshio, Ohara Shuta, Hamada Akira, Nishino Masaya, Chiba Masato, Shimoji Masaki, Takemoto Toshiki, Arita Takeo, Gmachl Michael, Hofmann Marco H, Soh Junichi, Mitsudomi Tetsuya
Abstract excerpt
INTRODUCTION: KRAS mutations have been recognized as undruggable for many years. Recently, novel KRAS G12C inhibitors, such as sotorasib and adagrasib, are being developed in clinical trials and have revealed promising results in metastatic NSCLC. Nevertheless, it is strongly anticipated that acquired resistance will limit their clinical use. In this study, we developed in vitro models of the KRAS G12C cancer,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.